Avid Bioservices Inc (CDMO)

[DewDiligence]

…release of HCV trial particulars at a medical conference should allow for a higher level of peer review and enables a more thorough characterization than sharing of preliminary results in a PR.

Once again, this is exactly the kind of shareholder gullibility that PPHM’s management is banking on.

The chance that there will actually be a peer-reviewed presentation of the phase-2 Bavi data in HCV is roughly comparable to the chance that an asteroid will destroy PPHM’s corporate headquarters in the next 10 minutes.